(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 February 2009 (19.02.2009)

PCT

(10) International Publication Number
WO 2009/022961 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 25/28* (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:
PCT/SE2008/050563

(22) International Filing Date: 14 May 2008 (14.05.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/938,005 15 May 2007 (15.05.2007) US
60/948,007 5 July 2007 (05.07.2007) US

(71) Applicants *(for all designated States except US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE). **ASTEX THERAPEUTICS LTD** [GB/GB]; 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CHESSARI, Gianni** [IT/GB]; Astex Therapeutics, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA (GB). **CONGREVE, Miles Stuart** [GB/GB]; Astex Therapeutics, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA (GB). **HOLENZ, Jörg** [DE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **MURRAY, Christopher** [GB/GB]; Astex Therapeutics, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA (GB). **PATEL, Sahil** [GB/GB]; Astex Therapeutics, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA (GB). **RAKOS, Laszlo** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **ROTTICCI, Didier** [FR/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).


(74) Agent: **ASTRAZENECA AB**; AstraZeneca Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(54) Title: PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS



I

(57) Abstract: This invention relates to novel compounds having the structural formula I below: (I) and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

WO 2009/022961 A1